Furthermore, the addition of liraglutide (a GLP-1 receptor agonist) to insulin therapy has also demonstrated potential benefits including but not limited to reduced HbA1c level, body weight, and insulin requirement in T1D patients (49, 61–63). This evidence concerns the gene GLP1R and type 1 diabetes mellitus.